IPAR vs RLX

IPAR exhibits exceptional financial health, highlighted by a perfect Piotroski F-Score of 9/9 and a very low Debt/Equity ratio of 0.19. While the current price of $93.00 sits above the conservative Graham Number ($56.90), it remains significantly discounted relative to its growth-based intrinsic value of $154.58 and the sector average P/E of 31.82. Despite bearish short-term technicals and recent insider selling, the company's strong ROE (20.34%) and consistent earnings beat track record suggest a high-quality compounder. The valuation gap between the current price and the analyst target of $111.20 provides a compelling margin of safety.

RLX exhibits strong fundamental health with a Piotroski F-Score of 8/9 and a nearly debt-free balance sheet (Debt/Equity 0.01). While the technical trend is currently bearish (0/100) and long-term price performance is poor, the company is significantly undervalued relative to its intrinsic value ($2.95) and trades at a low Price/Sales ratio of 0.74. Explosive YoY revenue growth (46.8%) and earnings growth (81.7%) suggest a powerful turnaround phase. The combination of high liquidity and a sustainable dividend makes this a high-conviction value play despite negative sentiment.